Skip to main content

Table 2 Adverse events by treatment group

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

VariablesRituximab group, n = 34IV-CY group, n = 20p value
All adverse events, no.19140.39
Death, no440.45
Sepsis (pyelonephritis)Bacterial pneumonia 
Invasive pulmonary aspergillosisPCP + invasive pulmonary aspergillosis 
Bacterial pneumoniaInvasive pulmonary aspergillosis 
StrokeSepsis (bacterial pneumonia) 
Leukopenia, no440.45
Thrombocytopenia, no421.00
Severe infection, no11120.09
CMV infection, n = 2PCP 
Bacterial pneumonia, n = 2CMV infection, n = 2 
Legionella pneumoniaAcute cholangitis 
Sepsis (pyelonephritis)Tuberculosis 
Invasive pulmonary aspergillosisPCP + invasive pulmonary aspergillosis 
PCPBacterial pneumonia, n = 4 
 Invasive pulmonary aspergillosis 
 Sepsis (bacterial pneumonia) 
VTE, no100.37
  1. The statistical difference was determined by chi-square test. Difference with p < 0.05 was considered significant
  2. PCP pneumocystis pneumonia, CBV cytomegalovirus, VTE venous thromboembolism